このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

The Effects of Exercise Snacks on Endothelial Function in Overweight Individuals

2026年11月11日 更新者:Weifang Medical University

This randomized controlled trial investigates the effects of two types of stair-climbing exercise snacks on vascular health, body composition, and blood lipids in overweight or obese adults. Participants will be assigned to one of three groups for 6-8 weeks. The control group receives no exercise intervention. Primary outcomes include endothelial function (ultrasound), body composition (InBody), and lipid profile (blood test).

調査の概要

詳細な説明

This is a parallel group randomized controlled trial, with the study subjects being overweight or obese adults (with a body mass index of ≥ 24 kg/m²). Participants will be recruited from universities and randomly assigned to one of the following three groups:

Short-term stair climbing exercise group Participants climbed the stairs 4 to 5 times a day, each time ascending 5 floors (approximately 1 minute each time). There was at least a 1-hour interval between each exercise session, and the exercises were carried out during daily activities. They exercised 3 to 5 times a week for 6 to 8 weeks.

Long-term stair climbing nutrition supplementation group The participants also conducted 4 to 5 stair climbing training sessions every day. Each training session consisted of 3 sets of climbing 5 floors (the total climbing height for each training session was 15 floors), with a rest period of no more than 1 minute between each set. The interval between two training sessions was no less than 1 hour. They exercised 3 to 5 times a week for 6 to 8 weeks.

Control group Participants maintained their daily activities and did not receive any exercise intervention measures.

Result measurement indicators:

Vascular health: Assessing endothelial function through ultrasound measurement of flow-mediated vascular dilation (FMD).

Body composition: Measured using the InBody body bioelectrical impedance analyzer (including muscle mass, fat mass and body fat percentage).

Blood lipid test: Collect fasting blood samples and measure low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglycerides (TG), and total cholesterol (TC).

Measurement time points: Measurements were conducted at the baseline (at the beginning of the study), 3-4 weeks (during the intervention period), and 8 weeks (after the intervention ended).

This research protocol has been approved by the Institutional Review Board of Shandong Second Medical University. All participants are required to sign a written informed consent form.

研究の種類

介入

入学 (実際)

51

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Shangdong
      • Weifang、Shangdong、中国、261053
        • Weifang Medical University

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~35年 (大人)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  1. Age: 18-35 years old (male, female);
  2. Clear consciousness, stable vital signs;
  3. Able to understand and follow simple instructions;
  4. No regular exercise for at least 3 months;
  5. BMI ≥ 24 kg/m2.

Exclusion Criteria:

  1. There are other serious diseases, such as tumors;
  2. There are other neurological diseases;
  3. There are serious diseases that simultaneously affect the heart, liver, kidneys, endocrine system or hematopoietic system;
  4. There is a history of alcohol or drug abuse;
  5. Participated in other clinical trials that might affect the results of this study;
  6. There are other neurological or musculoskeletal diseases, with pain worsening with exercise;
  7. It is forbidden to engage in physical training.
  8. Within the past 3 months, there have been acute cardiovascular events such as acute myocardial infarction,unstable angina pectoris, severe arrhythmia, acute heart failure, etc.;
  9. Uncontrolled hypertension;
  10. Severe pulmonary diseases, such as uncontrolled asthma, acute exacerbation of chronic obstructive pulmonary disease, interstitial lung disease with significant exercise limitation;
  11. Severe joint and bone diseases, acute soft tissue injuries, fractures that have not healed, etc., making it impossible to complete the prescribed exercise load;
  12. Presence of bleeding tendencies, coagulation dysfunction, or within the past 1 month, there has been major bleeding or a history of surgery;
  13. The investigator judges that there are any other situations that may affect the safety of the subjects or the results of the trial.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:防止
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:独身

武器と介入

参加者グループ / アーム
介入・治療
実験的:Short-term stair climbing exercise snack group

Participants perform short climbs of the stairs 4 to 5 times a day. Each climb involves going up 5 floors (approximately 1 minute), and there is a minimum interval of at least 1 hour between each climb.

Adopt a fragmented approach, climbing stairs 4-5 times a day, each time climbing 5 floors (approximately 1 minute per session), with at least 1 hour of interval between each session, and spread throughout the daily activity periods. Exercise 3-5 days per week for a total of 6-8 weeks.

実験的:Long-duration stair climbing exercise snack group

Participants climbed the ladder 4 to 5 times a day. Each climb consisted of 2 to 3 sets (each set involved climbing 5 floors, with a rest period of no more than 1 minute between sets), and the total number of floors climbed in a single session was 10 or 15.

On the basis of climbing stairs 4 to 5 times a day, increase the single exercise volume: complete 2 or 3 sets of climbing 5 floors of stairs each time (that is, the total number of floors climbed each time is 10 or 15), with no more than 1 minute of rest between sets. The intervals between each exercise should be at least 1 hour. Exercise 3 to 5 days a week, for a total of 6 to 8 weeks of intervention.

介入なし:control group

The participants did not undergo any form of exercise intervention and maintained their usual activity patterns.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Flow-mediated dilation (FMD, relative percentage)
時間枠:Measurements are conducted at the baseline, during the mid-intervention period (approximately 3-4 weeks), after the intervention concludes (6-8 weeks later), and at 4 weeks or 8 weeks of follow-up.

Flow-mediated dilation expressed as a percentage of the baseline brachial artery diameter.Unit of Measure: %

Measurements are conducted at the baseline, during the mid-intervention period (approximately 3-4 weeks), after the intervention concludes (6-8 weeks later), and at 4 weeks or 8 weeks of follow-up.
Absolute flow-mediated dilation (FMDabs)
時間枠:Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).

Absolute change in diameter, calculated as peak diameter minus basal diameter.Unit of Measure: mm

Measured at baseline, mid-intervention (approximately 3-4 weeks), and post-intervention (after 6-8 weeks).

二次結果の測定

結果測定
メジャーの説明
時間枠
Systolic blood pressure (SBP)
時間枠:Measurements are conducted at the baseline, during the mid-intervention period (approximately 3-4 weeks), after the intervention concludes (6-8 weeks later), and at 4 weeks or 8 weeks of follow-up.

Systolic blood pressure measured using an electronic sphygmomanometer.Unit of Measure: mmHg

Measurements are conducted at the baseline, during the mid-intervention period (approximately 3-4 weeks), after the intervention concludes (6-8 weeks later), and at 4 weeks or 8 weeks of follow-up.
Serum high-density lipoprotein (HDL) cholesterol concentration
時間枠:Measured at baseline and post-intervention (after 6-8 weeks).

Fasting serum HDL cholesterol concentration measured from blood samples. Unit of Measure: mmol/L

Measured at baseline and post-intervention (after 6-8 weeks).
Basal brachial artery diameter
時間枠:Measurements are conducted at the baseline, during the mid-intervention period (approximately 3-4 weeks), after the intervention concludes (6-8 weeks later), and at 4 weeks or 8 weeks of follow-up.

Baseline diameter of the brachial artery before cuff inflation.Unit of Measure: mm

Measurements are conducted at the baseline, during the mid-intervention period (approximately 3-4 weeks), after the intervention concludes (6-8 weeks later), and at 4 weeks or 8 weeks of follow-up.
Time to peak dilation
時間枠:Measurements are conducted at the baseline, during the mid-intervention period (approximately 3-4 weeks), after the intervention concludes (6-8 weeks later), and at 4 weeks or 8 weeks of follow-up.

Time required to reach maximal dilation after cuff deflation.Unit of Measure: seconds

Measurements are conducted at the baseline, during the mid-intervention period (approximately 3-4 weeks), after the intervention concludes (6-8 weeks later), and at 4 weeks or 8 weeks of follow-up.
Skeletal muscle mass
時間枠:Measurements are conducted at the baseline, during the mid-intervention period (approximately 3-4 weeks), after the intervention concludes (6-8 weeks later), and at 4 weeks or 8 weeks of follow-up.

Skeletal muscle mass measured by bioelectrical impedance analysis (InBody device).Unit of Measure: kg

Measurements are conducted at the baseline, during the mid-intervention period (approximately 3-4 weeks), after the intervention concludes (6-8 weeks later), and at 4 weeks or 8 weeks of follow-up.
Visceral fat area
時間枠:Measurements are conducted at the baseline, during the mid-intervention period (approximately 3-4 weeks), after the intervention concludes (6-8 weeks later), and at 4 weeks or 8 weeks of follow-up.

Visceral fat area measured by bioelectrical impedance analysis (InBody device). Unit of Measure: cm²

Measurements are conducted at the baseline, during the mid-intervention period (approximately 3-4 weeks), after the intervention concludes (6-8 weeks later), and at 4 weeks or 8 weeks of follow-up.
Waist circumference
時間枠:Measurements are conducted at the baseline, during the mid-intervention period (approximately 3-4 weeks), after the intervention concludes (6-8 weeks later), and at 4 weeks or 8 weeks of follow-up.

Waist circumference measured by bioelectrical impedance analysis (InBody device).Unit of Measure: cm

Measurements are conducted at the baseline, during the mid-intervention period (approximately 3-4 weeks), after the intervention concludes (6-8 weeks later), and at 4 weeks or 8 weeks of follow-up.
Basal metabolic rate (BMR)
時間枠:Measurements are conducted at the baseline, during the mid-intervention period (approximately 3-4 weeks), after the intervention concludes (6-8 weeks later), and at 4 weeks or 8 weeks of follow-up.

Basal metabolic rate estimated by bioelectrical impedance analysis (InBody device).Unit of Measure: kcal

Measurements are conducted at the baseline, during the mid-intervention period (approximately 3-4 weeks), after the intervention concludes (6-8 weeks later), and at 4 weeks or 8 weeks of follow-up.
Body mass index (BMI)
時間枠:Measurements are conducted at the baseline, during the mid-intervention period (approximately 3-4 weeks), after the intervention concludes (6-8 weeks later), and at 4 weeks or 8 weeks of follow-up.

Body mass index calculated from weight and height measured by bioelectrical impedance analysis (InBody device).Unit of Measure: kg/m²

Measurements are conducted at the baseline, during the mid-intervention period (approximately 3-4 weeks), after the intervention concludes (6-8 weeks later), and at 4 weeks or 8 weeks of follow-up.
Body fat percentage
時間枠:Measurements are conducted at the baseline, during the mid-intervention period (approximately 3-4 weeks), after the intervention concludes (6-8 weeks later), and at 4 weeks or 8 weeks of follow-up.

Body fat percentage measured by bioelectrical impedance analysis (InBody device).Unit of Measure: %

Measurements are conducted at the baseline, during the mid-intervention period (approximately 3-4 weeks), after the intervention concludes (6-8 weeks later), and at 4 weeks or 8 weeks of follow-up.
Body weight
時間枠:Measurements are conducted at the baseline, during the mid-intervention period (approximately 3-4 weeks), after the intervention concludes (6-8 weeks later), and at 4 weeks or 8 weeks of follow-up.

Body weight measured by bioelectrical impedance analysis (InBody device).Unit of Measure: kg

Measurements are conducted at the baseline, during the mid-intervention period (approximately 3-4 weeks), after the intervention concludes (6-8 weeks later), and at 4 weeks or 8 weeks of follow-up.
Peak brachial artery diameter
時間枠:Measurements are conducted at the baseline, during the mid-intervention period (approximately 3-4 weeks), after the intervention concludes (6-8 weeks later), and at 4 weeks or 8 weeks of follow-up.

Maximal diameter of the brachial artery after reactive hyperemia.Unit of Measure: mm

Measurements are conducted at the baseline, during the mid-intervention period (approximately 3-4 weeks), after the intervention concludes (6-8 weeks later), and at 4 weeks or 8 weeks of follow-up.
Body fat mass
時間枠:Measurements are conducted at the baseline, during the mid-intervention period (approximately 3-4 weeks), after the intervention concludes (6-8 weeks later), and at 4 weeks or 8 weeks of follow-up.

Body fat mass measured by bioelectrical impedance analysis (InBody device). Unit of Measure: kg

Measurements are conducted at the baseline, during the mid-intervention period (approximately 3-4 weeks), after the intervention concludes (6-8 weeks later), and at 4 weeks or 8 weeks of follow-up.
Diastolic blood pressure (DBP)
時間枠:Measurements are conducted at the baseline, during the mid-intervention period (approximately 3-4 weeks), after the intervention concludes (6-8 weeks later), and at 4 weeks or 8 weeks of follow-up.

Diastolic blood pressure measured using an electronic sphygmomanometer. Unit of Measure: mmHg

Measurements are conducted at the baseline, during the mid-intervention period (approximately 3-4 weeks), after the intervention concludes (6-8 weeks later), and at 4 weeks or 8 weeks of follow-up.
Heart rate
時間枠:Measurements are conducted at the baseline, during the mid-intervention period (approximately 3-4 weeks), after the intervention concludes (6-8 weeks later), and at 4 weeks or 8 weeks of follow-up.

Heart rate measured using an electronic sphygmomanometer.Unit of Measure: bpm (beats per minute)

Measurements are conducted at the baseline, during the mid-intervention period (approximately 3-4 weeks), after the intervention concludes (6-8 weeks later), and at 4 weeks or 8 weeks of follow-up.
Serum low-density lipoprotein (LDL) cholesterol concentration
時間枠:Measured at baseline and post-intervention (after 6-8 weeks).

Fasting serum LDL cholesterol concentration measured from blood samples. Unit of Measure: mmol/L

Measured at baseline and post-intervention (after 6-8 weeks).
Serum total cholesterol concentration
時間枠:Measured at baseline and post-intervention (after 6-8 weeks).

Fasting serum total cholesterol concentration measured from blood samples. Unit of Measure: mmol/L

Measured at baseline and post-intervention (after 6-8 weeks).
HDL/LDL cholesterol ratio
時間枠:Measured at baseline and post-intervention (after 6-8 weeks).

Ratio of serum HDL cholesterol to LDL cholesterol calculated from fasting blood samples.Unit of Measure: ratio (dimensionless)

Measured at baseline and post-intervention (after 6-8 weeks).
Serum triglyceride concentration
時間枠:Measured at baseline and post-intervention (after 6-8 weeks).

Fasting serum triglyceride concentration measured from blood samples.Unit of Measure: mmol/L

Measured at baseline and post-intervention (after 6-8 weeks).

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:YANXIA WANG, PhD、Weifang Medical University(Renamed Shandong Second Medical University)

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年4月20日

一次修了 (実際)

2026年6月16日

研究の完了 (実際)

2026年7月20日

試験登録日

最初に提出

2026年4月13日

QC基準を満たした最初の提出物

2026年4月22日

最初の投稿 (実際)

2026年4月30日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月17日

QC基準を満たした最後の更新が送信されました

2026年11月11日

最終確認日

2026年4月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する